These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36763205)

  • 1. Correction: PARP targeted Auger emitter therapy with [
    Sankaranarayanan RA; Florea A; Allekotte S; Vogg ATJ; Maurer J; Schäfer L; Bolm C; Terhorst S; Classen A; Bauwens M; Morgenroth A; Mottaghy FM
    EJNMMI Res; 2023 Feb; 13(1):12. PubMed ID: 36763205
    [No Abstract]   [Full Text] [Related]  

  • 2. PARP targeted Auger emitter therapy with [
    Ambur Sankaranarayanan R; Florea A; Allekotte S; Vogg ATJ; Maurer J; Schäfer L; Bolm C; Terhorst S; Classen A; Bauwens M; Morgenroth A; Mottaghy FM
    EJNMMI Res; 2022 Sep; 12(1):60. PubMed ID: 36104637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells.
    Chivot J; Ferrand N; Fert A; Van Dreden P; Morichon R; Sabbah M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.
    Sankaranarayanan RA; Peil J; Vogg ATJ; Bolm C; Terhorst S; Classen A; Bauwens M; Maurer J; Mottaghy F; Morgenroth A
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    Kawanishi M; Fujita M; Karasawa K
    Breast Cancer (Auckl); 2022; 16():11782234221080553. PubMed ID: 35340889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    Han Y; Li CW; Hsu JM; Hsu JL; Chan LC; Tan X; He GJ
    Am J Cancer Res; 2019; 9(4):800-815. PubMed ID: 31106005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
    Han Y; Chen MK; Wang HL; Hsu JL; Li CW; Chu YY; Liu CX; Nie L; Chan LC; Yam C; Wang SC; He GJ; Hortobagyi GN; Tan XD; Hung MC
    Am J Cancer Res; 2019; 9(3):608-618. PubMed ID: 30949414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma.
    Lee H; Riad A; Martorano P; Mansfield A; Samanta M; Batra V; Mach RH; Maris JM; Pryma DA; Makvandi M
    J Nucl Med; 2020 Jun; 61(6):850-856. PubMed ID: 31676730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.
    Sambade MJ; Van Swearingen AED; McClure MB; Deal AM; Santos C; Sun K; Wang J; Mikule K; Anders CK
    Neurooncol Adv; 2019; 1(1):vdz005. PubMed ID: 32642648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
    Keung MY; Wu Y; Badar F; Vadgama JV
    J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
    Cañedo EC; Totten S; Ahn R; Savage P; MacNeil D; Hudson J; Autexier C; Deblois G; Park M; Witcher M; Ursini-Siegel J
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33470989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
    Nguyen NT; Pacelli A; Nader M; Kossatz S
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
    J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.